ABSTRACT
PURPOSE Optimal patient selection for neoadjuvant chemotherapy prior to surgical extirpation is limited by the inaccuracy of contemporary clinical staging methods in high-risk upper tract urothelial carcinoma (UTUC). We investigated whether the detection of plasma circulating tumor DNA (ctDNA) can predict muscle-invasive and non-organ confined (MI/NOC) UTUC.
PATIENTS AND METHODS Plasma cell-free DNA was prospectively collected from chemotherapy-naïve, high-risk UTUC patients undergoing surgical extirpation and sequenced using a 152-gene panel and low-pass whole-genome sequencing. To test for concordance, whole exome sequencing was performed on matching tumor samples. The performance of ctDNA for predicting MI/NOC UTUC was summarized using area under a receiver-operating curve and the optimal variant count threshold determined using Younden’s J statistic. Kaplan-Meier methods estimated survival, and Mantel-Cox log-rank testing assessed the association between preoperative ctDNA positivity and clinical outcomes.
RESULTS Of 30 patients prospectively enrolled, 14 were found to have MI/NOC UTUC. At least one ctDNA variant was detected from 21/30 (70%) patients with 52% concordance with matching tumor samples. Detection of at least two panel-based molecular alterations provided the optimal sensitivity and specificity to predict MI/NOC UTUC. Imposing this threshold in combination with a plasma copy number burden score >6.5 achieved a sensitivity of 79% and specificity of 94% in predicting MI/NOC UTUC. Furthermore, the presence of ctDNA was strongly prognostic for progression-free survival (1-yr PFS 69% vs. 100%, p<0.01) and overall survival (1-yr OS 56% vs. 100%, p<0.02).
CONCLUSION The detection of plasma ctDNA prior to extirpative surgery was highly predictive of MI/NOC UTUC and strongly prognostic of PFS and OS. Preoperative ctDNA demonstrates promise as a biomarker for selecting patients to undergo neoadjuvant chemotherapy prior to nephroureterectomy.
Competing Interest Statement
DISCLOSURES BG Employment: Predicine Inc Stock: Predicine, Freenome, Myriad SJ Employment: Predicine, Inc, Roche/Genentech Stock: Predicine, Inc, Roche/Genentech WJS Advisory Board: Pacific Edge, Urogen GDG Stock: Natera Consulting: MyCareGorithm AN Employment: Bayer (immediate family member) Consultant/Advisory Role: Merck Sharp & Dohme, Roche, Bayer, AstraZeneca, Clovis Oncology, Janssen, Incyte, Seattle Genetics, Astellas, Bristol-Myers Squibb, Rainier Therapeutics, GlaxoSmithKline, Basilea Pharmaceuticals, Catalym Travel, Accommodation, Expenses: Roche, Merck Sharp & Dohme, AstraZeneca, Janssen, Rainier Therapeutics, Pfizer Other: Bayer (immediate family member) Stock or other ownership interest: Bayer (immediate family member) Honoraria: Roche, Merck, AstraZeneca, Janssen, Foundation Medicine, Bristol Myers Squibb, Astellas Pharm Research funding: Merck Sharp & Dohme (institution), AstraZeneca (institution), Ipsen, Gilead Sciences BMF Consulting: QED therapeutics, Boston Gene, Astrin Biosciences Advisory board: Merck, Immunomedics/Gilead, QED therapeutics, Guardant, Janssen Patent royalties: Immunomedics/Gilead Honoraria: Urotoday Research support: Eli Lilly Grants and research support: NIH, DoD CDMRP, Starr Cancer Consortium, P 1000 Consortium PD Employment: Predicine Inc Stock: Predicine, Inc RL Research support: Predicine; Veracyte; CG Oncology; Valar labs. Clinical trial protocol committee-CG Oncology. Scientific advisor/consultant-BMS, Merck, Fergene, Arquer Diagnostics, Urogen Pharma, Lucence.
Funding Statement
This research was supported by the H Lee Moffitt Cancer Center & Research Institute; Predicine, Inc; and the American Cancer Society-Institutional Research Grant from January 1-December 31, 2021. EAS and ACS were the recipients of support from the Junior Scientist Research Partnership award from Moffitt Cancer Center and Research Institute.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This work was approved by institutional review board of H Lee Moffitt Cancer Center and Research Institute.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
ABBREVIATIONS
- AUC
- Area under a receiver-operating curve
- cfDNA
- Cell-free DNA
- CNA
- Copy number alterations
- CNB
- Copy number burden
- ctDNA
- Circulating tumor DNA
- FFPE
- Formalin-fixed paraffin-embedded
- GA
- Genomic alterations
- gDNA
- Germline DNA
- indel
- Small insertion or deletion
- MA
- Molecular alteration
- MI/NOC
- Muscle-invasive/non-organ confined UTUC
- NAC
- Neoadjuvant chemotherapy
- NMI
- Non-muscle-invasive UTUC
- PBMC
- Peripheral blood mononuclear cell
- PFS
- Progression-free survival
- RNU
- Radical nephroureterectomy
- SNV
- Single nucleotide variation
- UTUC
- Upper tract urothelial carcinoma
- WGS
- Whole genome sequencing
